m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG02258)
Name
Coumestrol
Synonyms
3,9-Dihydroxy-6H-[1]benzofuro[3,2-c]chromen-6-one; 3,9-Dihydroxy-6H-benzofuro(3,2-c)(1)benzopyran-6-one; 3,9-Dihydroxycoumestan; 479-13-0; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-; 6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-; 7,12-Dihydroxycoumestan; BRN 0266702; CCRIS 7311; CHEBI:3908; CHEMBL30707; COUMESTROL; Coumesterol; Cumoesterol; Cumoestrol; Cumostrol; EINECS 207-525-6; MLS000738006; NSC 22842; NSC22842; UNII-V7NW98OB34; V7NW98OB34; ZZIALNLLNHEQPJ-UHFFFAOYSA-N
    Click to Show/Hide
Status
Preclinical
Structure
Formula
C15H8O5
InChI
1S/C15H8O5/c16-7-1-3-9-11(5-7)19-14-10-4-2-8(17)6-12(10)20-15(18)13(9)14/h1-6,16-17H
InChIKey
ZZIALNLLNHEQPJ-UHFFFAOYSA-N
PubChem CID
5281707
VARIDT Drug ID
DR00932
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Breast cancer resistance protein (ABCG2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Breast cancer resistance protein (ABCG2) is a therapeutic target for Coumestrol. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of Coumestrol through regulating the expression of Breast cancer resistance protein (ABCG2). [1], [2]
References
Ref 1 METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner. Exp Mol Med. 2021 Jan;53(1):91-102. doi: 10.1038/s12276-020-00510-w. Epub 2021 Jan 8.
Ref 2 Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol Pharmacol. 2007 Oct;72(4):967-75.